Securing access to optimal cancer care through innovation, integration and sustainability

ScienceDaily | 10/19/2018 | Staff
jollyjetta (Posted by) Level 3
At the opening press conference of ESMO 2018 Congress, Scientific Chair, Professor Solange Peters stressed the importance of ensuring that the innovations reported at the meeting reach the right patients at the right time.

"ESMO 2018 is first and foremost about innovation, and compelling clinical trial data will be presented about potential new treatments for breast, prostate, ovarian and other cancers. But the conference is also about integration and sustainability, and we are encouraging a more integrated approach to cancer care as well as supporting essential policy-informing discussions about affordable, sustainable models of care," she said.

Days - Data - Abstracts - Patients - Part

Over the next few days, data will be presented from over 2000 submitted abstracts, representing nearly 116,000 patients who have taken part in clinical trials. Amongst studies focused on access to care will be important research demonstrating large variations between countries in time for reimbursement decisions on new cancer drugs. This shows that some European countries take more than twice as long as others to reach health technology assessment (HTA) decisions to reimburse new cancer drugs following their approval by the European Medicines Agency (EMA). The average decision time is longer than one year in some countries (1).

"Without timely reimbursement...
(Excerpt) Read more at: ScienceDaily
Wake Up To Breaking News!
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!